Overview

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ambrisentan